FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency
Links shared publicly online about this topic.
- 1,402total visits
FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency
Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled t
View full resource at news-medical.net
Tags: COPD, Disease and Condition, Drug, FDA
Most Recently Shared on February 6, 2010 at 7:00 am By:
Medicare News: FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to trea... http://bit.ly/9T7yWx
Also Shared By:
Orphan drug designation granted for aerosolized alpha1-proteinease inhibitor for alpha1-antitrypsin deficiency - MPR
empr.com — “Talecris Biotherapeutics was granted orphan drug designation by the FDA for the development of an aerosol formulation of alpha1-proteinease inhibitor to treat congenital alpha1-antitrypsin (AAT) deficiency.” View full resource at empr.com
Most Recently Shared on February 8, 2010 at 5:29 pm By:
MPR News: Orphan drug designation granted for aerosolized alpha1-proteinease inhibitor for alpha1-antitrypsin defi... http://bit.ly/9gpJZZ
Advertisement
News-Medical.Net
@NewsMedical
FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficienc... http://bit.ly/9T7yWx
1 year ago...